Hims & Hers Health (NYSE: HIMS) shares surged more than 36% in premarket trading today after revealing a new collaboration with Novo Nordisk (NYSE: NVO) to distribute Wegovy, the blockbuster weight management medication, through the Hims & Hers platform.
Through the new agreement, NovoCare Pharmacy, Novo’s direct-to-consumer service, will be made available to Hims & Hers members, giving patients access to the full range of Wegovy doses. The companies announced the offering will roll out later this week, describing it as the beginning of a broader long-term collaboration.
Shares of LifeMD (NASDAQ: LFMD) also rallied, gaining over 21%, after it announced it would offer all Wegovy dose options via its virtual care services for cash-paying customers.
The news marks an important step forward for Hims & Hers. The company had previously faced pressure from investors after the FDA confirmed the end of Wegovy supply shortages earlier this year, putting their compounded semaglutide offerings—introduced in May 2025 at a steep discount—under the spotlight.
This new partnership helps position Hims & Hers as a trusted channel for branded GLP-1 therapies, strengthening its growth strategy beyond compounded medications.
“We’re thrilled to collaborate with Novo Nordisk, a leader in medical innovation with a world-class treatment portfolio,”
— Andrew Dudum, CEO of Hims & Hers
The announcement follows Hims & Hers’ recent decision to add branded tirzepatide therapies from Eli Lilly (NYSE: LLY) to their platform, reinforcing the company’s ambition to be a major digital access point for the next generation of weight loss solutions.
Highlights:
- 📈 HIMS stock climbed ~36%; LFMD stock rose ~21% after announcements
- 💊 Full range of Wegovy doses will be offered to Hims & Hers members
- 🤝 Signals a deeper strategic partnership with Novo Nordisk over time
- 🌐 Positions Hims & Hers as a key digital player in the GLP-1 market
- 🔄 Reinforces shift away from compounded drug strategies
